Subtopic Deep Dive
Gut-Liver Axis in Cirrhosis
Research Guide
What is Gut-Liver Axis in Cirrhosis?
The gut-liver axis in cirrhosis describes bidirectional interactions between gut microbiota dysbiosis, bacterial translocation, endotoxemia, and liver inflammation exacerbating portal hypertension and decompensation.
Intestinal barrier dysfunction in cirrhosis promotes pathogen-associated molecular patterns crossing into portal circulation, triggering hepatic inflammation (Fukui and Wiest, 2016; 6808 citations). This axis links microbiota changes to complications like hepatic encephalopathy and acute-on-chronic liver failure. Over 20 key papers since 2010 explore modulation via probiotics or fecal transplants.
Why It Matters
Dysbiosis-driven endotoxemia worsens portal hypertension and systemic inflammation in cirrhosis patients, increasing decompensation risk (Fukui and Wiest, 2016). Fecal microbiota transplantation from rational donors reduces recurrent hepatic encephalopathy readmissions by restoring microbiota balance (Bajaj et al., 2017; 598 citations). These insights support microbiota-targeted therapies to prevent infections and improve survival in decompensated cirrhosis (Angeli et al., 2018).
Key Research Challenges
Quantifying Bacterial Translocation
Direct measurement of bacterial translocation in cirrhosis remains invasive and indirect, relying on serum markers like lipopolysaccharide-binding protein. Studies link dysbiosis to leaky gut but lack standardized assays for clinical use (Giannelli, 2014; 217 citations). This hampers early intervention before decompensation.
Microbiota Modulation Efficacy
Probiotics and fecal transplants show promise in hepatic encephalopathy but face variability in donor selection and sustained engraftment (Bajaj et al., 2017). Trials report short-term benefits yet struggle with long-term microbiota stability in portal hypertension. Optimizing protocols requires longitudinal multi-omics data.
Distinguishing Causality from Correlation
Observational data associate gut dysbiosis with cirrhosis progression, but causality versus epiphenomenon debates persist due to confounding factors like alcohol use (Tilg et al., 2022). Animal models confirm barrier disruption prerequisites but human translation lags (Mouriès et al., 2019; 611 citations).
Essential Papers
Changes of Intestinal Functions in Liver Cirrhosis
Hiroshi Fukui, Reiner Wiest · 2016 · Inflammatory Intestinal Diseases · 6.8K citations
<b><i>Background:</i></b> Understanding of the gut-liver axis is important for the up-to-date management of liver cirrhosis, and changes of intestinal functions form the cor...
Expanding consensus in portal hypertension
Roberto de Franchis · 2015 · Journal of Hepatology · 3.0K citations
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
Paolo Angeli, Mauro Bernardi, Càndid Villanueva et al. · 2018 · Journal of Hepatology · 2.7K citations
Gut-liver axis: Pathophysiological concepts and clinical implications
Herbert Tilg, Timon E. Adolph, Michael Trauner · 2022 · Cell Metabolism · 612 citations
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development
Juliette Mouriès, Paola Brescia, Alessandra Silvestri et al. · 2019 · Journal of Hepatology · 611 citations
Acute-on-chronic liver failure: an update
Rubén Hernáez, Elsa Solà, Richard Moreau et al. · 2017 · Gut · 601 citations
Acute-on-chronic liver failure (ACLF) is a syndrome characterised by acute decompensation of chronic liver disease associated with organ failures and high short-term mortality. Alcohol and chronic ...
Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial
Jasmohan S. Bajaj, Zain Kassam, Andrew Fagan et al. · 2017 · Hepatology · 598 citations
Recurrent hepatic encephalopathy (HE) is a leading cause of readmission despite standard of care (SOC) associated with microbial dysbiosis. Fecal microbiota transplantation (FMT) may improve dysbio...
Reading Guide
Foundational Papers
Start with Fukui and Wiest (2016; 6808 citations) for core intestinal function changes; Giannelli (2014; 217 citations) on translocation and infection; Rai et al. (2014; 171 citations) links microbiota to hepatic encephalopathy mechanisms.
Recent Advances
Tilg et al. (2022; 612 citations) updates pathophysiologic concepts; Bajaj et al. (2017; 598 citations) validates FMT trials; Mouriès et al. (2019; 611 citations) demonstrates vascular barrier role.
Core Methods
16S rRNA and metagenomics for dysbiosis; lipopolysaccharide-binding protein for endotoxemia; randomized controlled trials for probiotics/FMT; multi-omics integration for causality.
How PapersFlow Helps You Research Gut-Liver Axis in Cirrhosis
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to map core works like Fukui and Wiest (2016; 6808 citations), revealing clusters around bacterial translocation; exaSearch uncovers niche trials on fecal transplants, while findSimilarPapers expands from Bajaj et al. (2017) to 50+ related studies on encephalopathy.
Analyze & Verify
Analysis Agent applies readPaperContent to extract microbiota composition data from Bajaj et al. (2017), then runPythonAnalysis with pandas to quantify dysbiosis metrics across cohorts; verifyResponse via CoVe cross-checks claims against Angeli et al. (2018) guidelines, with GRADE grading for evidence strength in decompensated cirrhosis management.
Synthesize & Write
Synthesis Agent detects gaps in long-term fecal transplant outcomes post-Bajaj et al. (2017), flags contradictions between animal barrier models (Mouriès et al., 2019) and human data; Writing Agent uses latexEditText, latexSyncCitations for review drafts, and latexCompile to generate polished manuscripts with exportMermaid diagrams of gut-liver signaling pathways.
Use Cases
"Analyze microbiota alpha diversity changes in HE patients from Bajaj 2017 trial using Python."
Research Agent → searchPapers('Bajaj 2017') → Analysis Agent → readPaperContent → runPythonAnalysis(pandas alpha diversity stats on 16S data) → matplotlib plots of pre/post-FMT diversity.
"Draft LaTeX review section on gut dysbiosis in cirrhosis citing Fukui 2016 and Tilg 2022."
Research Agent → citationGraph → Synthesis Agent → gap detection → Writing Agent → latexEditText(draft section) → latexSyncCitations(Fukui, Tilg) → latexCompile(PDF with figure captions).
"Find GitHub repos analyzing 16S rRNA data from cirrhosis microbiota studies."
Research Agent → searchPapers('gut-liver cirrhosis microbiota') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(QIIME2 pipelines) → runPythonAnalysis(reproduce diversity metrics).
Automated Workflows
Deep Research workflow conducts systematic reviews by chaining searchPapers on 'gut-liver axis cirrhosis' (50+ papers from Fukui 2016 hub), citationGraph clustering, and GRADE-graded summaries of translocation evidence. DeepScan applies 7-step analysis with CoVe checkpoints to verify FMT efficacy in Bajaj et al. (2017) against de Franchis (2015) portal hypertension consensus. Theorizer generates hypotheses on barrier-targeted therapies from Mouriès et al. (2019) vascular disruption data.
Frequently Asked Questions
What defines the gut-liver axis in cirrhosis?
It encompasses microbiota dysbiosis, impaired intestinal barrier leading to bacterial translocation, portal endotoxemia, and hepatic inflammation driving decompensation (Fukui and Wiest, 2016).
What methods study this axis?
16S rRNA sequencing quantifies dysbiosis, serum lipopolysaccharide assays detect translocation, and randomized trials test fecal microbiota transplants (Bajaj et al., 2017).
What are key papers?
Fukui and Wiest (2016; 6808 citations) detail intestinal changes; Bajaj et al. (2017; 598 citations) prove FMT efficacy in encephalopathy; Tilg et al. (2022) review pathophysiological concepts.
What open problems exist?
Sustained microbiota engraftment post-FMT, causal translocation assays, and personalized modulation strategies in portal hypertension remain unresolved (Angeli et al., 2018).
Research Liver Disease and Transplantation with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Gut-Liver Axis in Cirrhosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
Part of the Liver Disease and Transplantation Research Guide